Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis [PDF]
Frontiers in MedicineBackgroundAlopecia areata (AA) is a chronic immune-mediated disorder causing non-scarring hair loss. Severe forms like alopecia totalis (AT) and alopecia universalis (AU) pose therapeutic difficult situations.
Natsuko Saito-Sasaki +2 more
exaly +4 more sources
Case Report: A novel KRT74 variant in an eight-year-old boy with alopecia totalis successfully treated with baricitinib [PDF]
Frontiers in MedicineAlopecia areata is an autoimmune condition characterized by non-scarring hair loss, with genetic factors playing a significant role in disease susceptibility.
Weinan Zhou, Jianying Liang, Yidong Tan
exaly +4 more sources
A case of unusual comedogenesis in alopecia totalis [PDF]
Indian Dermatology Online Journal, 2022 Balkrishna P Nikam +3 more
doaj +4 more sources
Effective management Alopecia totalis by Ayurveda – A case report [PDF]
Journal of Ayurveda and Integrative Medicine, 2023 Alopecia areata (AA) is a T-cell-mediated autoimmune illness characterized by intermittent, non-scarring hair loss, Alopecia totalis(AT) is a type of AA characterized by total hair loss on the face and scalp.
Shivanand B. Patil +2 more
doaj +2 more sources
Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series [PDF]
ReportsBackground: Alopecia areata is an autoimmune disorder characterized by nonscarring hair loss, which can progress to alopecia totalis or universalis.
Waleed Alajroush +5 more
doaj +2 more sources
Omega Fatty Acids in Hair Loss Disorders: A Scoping Review of Preclinical and Clinical Evidence [PDF]
J Cosmet DermatolABSTRACT Background Omega fatty acids, including polyunsaturated omega‐3 and omega‐6 fatty acids (PUFAs) and monounsaturated omega‐9 fatty acids, regulate inflammation, cellular signaling, and tissue homeostasis, and may influence hair follicle biology and hair growth.
Abdul‐Rahman N +6 more
europepmc +2 more sources
Alopecia Risk With GLP‐1 Receptor Agonists: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) [PDF]
J Cosmet DermatolABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1‐RAs), a class of drugs indicated for diabetes mellitus and weight control, have been implicated in alopecia. We mined data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to better understand the relationship between alopecia and GLP‐1‐RAs.
Gupta A +4 more
europepmc +2 more sources
Alopecia Totalis Treated with 1064 nm Picosecond Nd:YAG Laser: A Case Report
Applied Sciences (Switzerland), 2019 Alopecia areata (AA) is an autoimmune disorder causing nonscarring hair loss. Alopecia totalis (AT), the severe form of AA, is usually refractory to many first-line treatments including topical and intralesional corticosteroids and topical immunotherapy.
Ching-chi Chi +2 more
exaly +3 more sources
Perceived Stress, Illness and Stigma in Patients with Alopecia Areata [PDF]
Acta Dermato-VenereologicaAlopecia areata is a nonscarring autoimmune hair loss disorder. Little is known about patients’ perceptions of their condition. This French cross-sectional online study primarily aimed to assess patients’ perception of stress as a causal factor, with ...
Maud Pellant +5 more
doaj +2 more sources
Clinical Characteristics, Treatment Patterns, and Outcomes of Chinese Patients With Alopecia Areata: A Retrospective Observational Study [PDF]
J Cosmet DermatolABSTRACT Background Alopecia areata (AA) is an inflammatory, nonscarring hair loss disorder with significant variations in the clinical presentation and unpredictable nature of the disease. Although AA is common in clinical dermatology, knowledge gaps remain regarding the clinical characteristics and impact on patients' psychological well‐being and ...
Sheng Y +9 more
europepmc +2 more sources